{"id":"standard-treatment-covid-19-triazavirin","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hematologic abnormalities"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triazavirin acts as a broad-spectrum antiviral by mimicking nucleosides and interfering with viral RNA-dependent RNA polymerase, thereby blocking viral genome replication. When combined with standard COVID-19 treatment protocols, it is intended to enhance antiviral efficacy and reduce viral load in infected patients.","oneSentence":"Triazavirin is a nucleoside analog that inhibits viral RNA polymerase to reduce SARS-CoV-2 replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:31.867Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (in combination with standard treatment)"}]},"trialDetails":[{"nctId":"NCT04973462","phase":"PHASE4","title":"Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2021-08-01","conditions":"Covid19","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["standard treatment COVID-19 + Oseltamivir"],"phase":"marketed","status":"active","brandName":"standard treatment COVID-19 + Triazavirin","genericName":"standard treatment COVID-19 + Triazavirin","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triazavirin is a nucleoside analog that inhibits viral RNA polymerase to reduce SARS-CoV-2 replication. Used for COVID-19 (in combination with standard treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}